Update on technologies, medicines and treatments

We know that being more active is important for preventing type 2 diabetes and managing blood glucose levels, but a recent study has looked specifically at walking and whether the speed you move can have an impact on your risk of developing type 2 diabetes.1 Researchers collected data from 10 prospective cohort studies undertaken in the United States, Japan and the United Kingdom. The duration of the studies was between 3 and 11 years. Walking speed was divided in to four categories—easy or casual (less than 2 mph), average or normal (2–3 mph), fairly brisk (3–4 mph) and very brisk or brisk/striding (greater than 4 mph). People who walk at the average speed had a 15% lower risk of developing type 2 diabetes than those who walk at the easy/casual speed and those who walked at a fairly brisk pace had a 24% lower risk. Those who walked the fastest had nearly a 40% lower relative risk. They also looked at whether adjusting for total physical activity or time spent walking per day changed these findings, but walking at a faster pace still showed benefits for reducing risk, regardless of these factors. The researchers pointed out some limitations to their study, as the different cohort studies did not all measure walking speed or diagnosis of type 2 diabetes in the same way. They also point out that participants with faster walking speed are more likely to perform more physical activity and have better cardiorespiratory fitness, greater muscle mass and better health status. But overall, they concluded that increasing the pace when you walk could be an extra boost for preventing type 2 diabetes, on top of just walking more in general. Researchers at Texas A&M University have found evidence suggesting a connection between type 2 diabetes and Alzheimer's disease. In their study, which has not yet been published in a scientific journal, the researchers investigated how these two diseases are related by conducting experiments on mice. They discovered that a specific protein in the gut, called jak3, is affected by consuming a high-fat diet. When this protein is suppressed, mice experienced inflammation starting from the intestine, spreading to the liver and the brain. These mice then displayed symptoms similar to Alzheimer's, such as memory loss. The researchers propose that managing or avoiding type 2 diabetes could potentially reduce the risk of Alzheimer's disease. Previous studies have shown a link between diet, lifestyle and the development of both diabetes and Alzheimer's. Additionally, the researchers found that the jak3 protein is associated with a condition called leaky gut, which causes chronic inflammation and may contribute to the development of type 2 diabetes, as well as impair the brain's ability to clear toxins, leading to dementia-like symptoms. By adopting a healthy diet and managing blood sugar levels, it might be possible to prevent or mitigate these diseases. This could involve starting healthy eating habits early or making lifestyle changes to prevent the onset of high blood sugar or reverse prediabetes. Around 81% of people with Alzheimer's also have type 2 diabetes, with the risk of dementia increasing with earlier onset of diabetes. Some researchers even refer to this link as ‘type 3 diabetes’. Experts believe that high blood sugar levels can damage the brain over time, increasing the risk of Alzheimer's. Treating type 2 diabetes involves preventing it from causing other health issues, such as heart disease and obesity. In the United States, doctors recently performed groundbreaking surgery where they transplanted a pig's kidney into a person for the first time. This was possible because scientists changed the genetic makeup of the kidney and used a new antirejection drug. This is not the first time a pig organ has been used in a human. In the past, people who had transplants of pig hearts only survived for a few months. The recipient lives with diabetes and high blood pressure. He had a human kidney transplant before, but it stopped working last year. He decided to try the pig kidney transplant because he thought it might help him and give hope to others who need transplants too. The surgery was allowed under a special rule called compassionate use by the FDA. This rule lets people with serious illnesses try new treatments when there is nothing else that can help them. Transplantation from non-human species, called xenotransplantation, uses advanced biotechnology. CRISPR was used to modify the genetic structure of the kidney, removing potentially harmful pig genes and adding certain human genes to improve its compatibility. They also inactivated porcine endogenous retroviruses in the pig kidney to eliminate any risk of infection in humans, which were the cause of death in one of the earlier transplants. The as yet unlicensed drug used to prevent rejection is tegoprubart alongside another off-label use of ravulizumab. These drugs are not commonly used yet, but they are being tested to see if they can help people receiving organ transplants. Doctors are excited about this new approach because of the shortage of donated human kidneys, leaving many people on dialysis for years. If it can be shown to be safe and effective, xenotransplantation might be a solution to this problem, but further research and long-term review will be needed to make it a reality. A new system for managing insulin in people with type 1 diabetes, controlled by a smart computer program, might work just as well as the traditional method based on equations, according to research from the University of Virginia. With continuous glucose data, they are teaching an artificial intelligence neural network to act as a closed-loop insulin delivery system called a Neural-Net Artificial Pancreas (NAP). To make this work, researchers train the neural network using a lot of data covering all the possible actions an automated insulin delivery system might take. They have already developed one of these smart artificial pancreases and are testing it in two clinical trials approved by the FDA. In one trial, they compared it to a typical insulin delivery method using a closed-loop system.2 During the trial, participants wore a device controlled by either the smart artificial pancreas or the traditional algorithm for 18 h. Then they switched to the other method. The results showed that the smart artificial pancreas performed similarly to the traditional method, keeping blood sugar levels in check. There is also another trial where participants used the smart artificial pancreas continuously for 5 days. The results were promising, showing that it kept blood sugar levels stable even without strict meal and activity guidelines. Overall, the smart artificial pancreas seems to be a promising tool for managing insulin in people with type 1 diabetes. It might even work better on small devices with limited processing power. This could be a step towards fully automated insulin management systems in the future. New data suggest that the level of HbA1c can predict the likelihood of adolescents with overweight or obesity developing type 2 diabetes.3 Over a 10-year period, researchers looked at a large group of young people in California. They found that while the overall rate of type 2 diabetes was low among adolescents with overweight or obesity, the risk increased for those with higher HbA1c levels. The study reviewed data on 74,552 children and adolescents aged 10–17 years with overweight or obesity. Compared with a baseline HbA1c of less than 37 mmol/mol (5.5%), risk increased 9-fold for HbA1c of 41 mmol/mol (5.9%–6.0%), 23-fold for 43–44 mmol/mol (6.1%–6.2%) and 72-fold for 45–46 mmol/mol (6.3%–6.4%). For those in the lowest HbA1c ranges of 39–40 mmol/mol (5.7%–5.8%), the annual incidence of type 2 diabetes was only 0.2% which is much lower than in a similar group of adults. The authors suggested that these adolescents would probably benefit from some form of lifestyle intervention but probably did not require annual screening, whereas those at HbA1c over 42 mmol/mol (6%) should be screened regularly. In total, 698 people of the group developed diabetes during the study, with almost 90% of them being diagnosed with type 2 diabetes. On average, it took about 3.8 years from when they first entered the study until they were diagnosed. The study also found that the risk of type 2 diabetes increased with greater obesity severity. Additionally, there were differences in risk based on gender and ethnicity, with women and certain ethnic groups showing higher incidence rates. This suggests that we should be checking HbA1c on young people with overweight or obesity to try and identify those most at risk of going on to develop type 2 diabetes so that actions to prevent its onset can be taken early. Insulin icodec is a new kind of insulin that only needs to be injected once a week. It is being reviewed by the European Medicines Agency but is currently only licensed in Canada. The hope is that this might help people with type 2 diabetes self-manage more effectively and feel more satisfied with their treatment, as they do not have to inject themselves as often. This study aimed to find out if once-weekly insulin icodec is as effective and safe as other types of insulin for managing type 2 diabetes.4 The study was a meta-analysis of all the studies, where people with type 2 diabetes were given insulin icodec and compared it with other types of long-acting analogue insulin in randomized controlled trials. They reviewed five clinical trials involving 3764 people. They found that once-weekly insulin icodec helped reduce HbA1c, slightly more than other insulin types did. More people using insulin icodec achieved a target HbA1c level of less than 53 mmol/mol (7%) compared to those using other insulin types, and they did so without experiencing low blood sugar levels as often. The time spent in the target range for blood sugar levels was similar between insulin icodec and other types of insulin. Overall, the side effects and adverse events related to insulin were similar between insulin icodec and other types of insulin. They concluded that once-weekly insulin icodec seems to be better at reducing HbA1c levels and helping people reach their blood sugar targets compared to other types of insulin that need to be injected daily. There were not any major safety concerns regarding low blood sugar levels or other side effects. In February, the FDA issued a warning against the use of smartwatches or smart rings that claim they can measure blood sugar levels without pricking the skin and drawing blood.5 They stress that no such devices have been approved yet, and using them could be risky. The same is true in the United Kingdom, where there are currently no MHRA-approved non-invasive monitors. These devices are different from the ones that display data on an app from approved glucose monitors that do require pricking the skin, like continuous glucose monitoring devices (CGMs). The warning applies to any smartwatch or smart ring claiming to measure blood sugar without skin piercing, no matter who makes it. While big companies like Apple and Samsung, as well as startups such as Movano, in the United States and Afon Technology, based in Wales, are working on non-invasive blood sugar monitoring tech, it remains experimental. The danger of using these unapproved devices is serious because they could give inaccurate readings, leading people with diabetes to make wrong decisions on treatment or missing episodes of hypo- or hyperglycaemia. These unapproved devices are being sold online and on social media, with many listings claiming to measure blood sugar, as well as other unlikely things like blood lipids and uric acid levels. A simple Google search found many of these devices available in the United Kingdom from about £39.99. Some manufacturers try to get around rules by saying their products are not medical devices, such as one that says in large print ‘Say goodbye to blood collection. No pain and no needles’ and then in much smaller print adds ‘This product is not a medical product, the measurement data is for reference only, and cannot be used as a medical clinical diagnosis report’. If a device claims to diagnose, treat or prevent a disease or affect the body's function and it is not a drug, it falls under medical device regulations and needs appropriate approval. The FDA, and Diabetes UK, would strongly advise against buying or using these smartwatches or smart rings, just because they are non-invasive. Research from the New York Eye and Ear Infirmary of Mount Sinai suggests that a sophisticated AI system, known as GPT-4 from Open AI, can be as good as or even better than human eye doctors at diagnosing and treating conditions like glaucoma and retinal diseases.6 This AI system is trained on a huge amount of data, including text and images, and it could become a valuable tool for supporting eye doctors in making decisions about these conditions, which affect millions of people. In their study, researchers compared the performance of GPT-4 with that of 12 eye specialists and 3 senior trainees from Mount Sinai. They asked them a set of common questions about glaucoma and retinal diseases and presented them with patient cases. The responses from both the AI system and the human specialists were then analysed and rated for accuracy and thoroughness. The results showed that the AI system performed as well as or better than the human specialists in giving accurate and comprehensive medical advice. It was especially good at answering questions about glaucoma and providing advice on how to manage cases, while it was equally accurate but more thorough than humans in responding to retina-related questions. According to Dr. Andy Huang, who led the study, this AI system has the potential to assist eye specialists by providing diagnostic support, particularly in complex cases or when there is a high number of patients. This could lead to quicker access to expert advice for patients and help doctors make more informed decisions about their treatment. Although more testing is needed, this research suggests a promising future for AI in the field of ophthalmology, where it could improve patient care and lighten the workload of eye specialists. A new computer program has been developed to help predict when patients in hospital might experience hypoglycaemia. This program, based on artificial intelligence, focuses solely on using blood sugar measurements taken from a finger prick test. According to a study presented at the Diabetes UK Professional Conference 2024, the program has shown to be very accurate in foreseeing hypoglycaemic events.7 The researchers also looked into which aspects of blood sugar levels were most important for predicting these events. They found that extreme and fluctuating blood sugar levels were the strongest indicators of potential hypoglycaemia. Dr. Chris Sainsbury and his team from Gartnavel General Hospital in Glasgow, Scotland, spearheaded this study. They emphasized that preventing hypoglycaemia is crucial, as it can lead to serious health issues for patients with diabetes during their hospital stay. The program analyses blood sugar data obtained from over 250,000 patients from routine tests and used it to calculate the likelihood of a hypoglycaemic event occurring within the next day or week. This information could help hospital staff intervene early to prevent such events. Dr. Sainsbury and his team plan to test the program in different hospital settings to see how well it works in real-world situations. They hope that by identifying patients at risk early on, they can reduce the incidence of hypoglycaemic events and improve patient outcomes. Over 1 billion people worldwide, including children, teens and adults, are living with obesity, making it a widespread problem. This number has been reached sooner than expected, mainly due to a shift from people being underweight to becoming obese, particularly in lower income and middle-income countries. A recent study involving over 1500 researchers from various organizations analysed data from more than 220 million individuals across nearly 200 countries.8 They looked at both underweight and obesity rates, which are two different types of malnutrition harmful to health. Adults were considered obese if their body mass index (BMI) was 30 or higher, while children and teens were classified based on their age and sex. The findings revealed that in 2022, nearly 880 million adults and 159 million children were living with obesity. Shockingly, obesity rates among children and teens have quadrupled since 1990, while rates among adults have more than doubled. Interestingly, the analysis showed a decline in underweight cases in most with obesity rates underweight rates in of the This has been particularly in and middle-income with like the and the experiencing high obesity rates. associated with for the United States, were not on top of the for obesity This shift towards obesity the need for particularly in systems effective Experts the of both obesity and underweight These could involve like aimed at children and in like and the need to work by to this It is to access to healthy and health over There have been some of changes such as plan and in regarding and of These the potential for that healthy eating and physical activity within This will also have an impact on the rates of type 2 diabetes A new from the Diabetes suggests using a glucose test to better people at risk of developing type 2 The is that some individuals might have normal glucose based on tests like HbA1c or but they could a glucose Dr. the lead of the that the glucose test is more in these individuals early This a of reviewed the evidence and a algorithm for identifying those with and type 2 diabetes. The involves using a to identify by a glucose test for those as high risk. If the glucose level is a certain individuals are considered to have or even type 2 diabetes, on the changes and further are for those as high risk. The is based on research showing that the glucose test is a better of future diabetes and related than other tests like the glucose test. some concerns about the of this test in clinical settings and its impact on outcomes. The to a between normal blood sugar levels and diabetes. This to individuals in this early to prevent to diabetes. While some researchers the use of the glucose others that on lifestyle and managing risk like obesity and may be more effective in preventing diabetes. the Diabetes the glucose test is a simple and especially for and countries. Overall, the hope is that organizations like the Diabetes and the will this to improve diabetes and from a study presented at the Diabetes UK Professional suggest that a special device called can help improve various health in people with type 2 diabetes and obesity. The study, led by Dr. from showed that 1 of the in their gut, patients experienced better of blood sugar levels and in liver 2 years of removing the of patients to see in their health. is a in the first of the small intestine, preventing some from being This changes in how the body glucose and is and involves a simple During the study, patients a special diet the device They to over When the device was a patients had an average of about 37 and their blood sugar levels had years the more than of the patients their and blood sugar Some even stopped insulin. about of patients to their health status. its some patients experienced side effects like issues, but they fully the device was In the the development of human insulin in the all insulin was from mainly and then used human into such as to the first human insulin. scientists from the University of and have with a groundbreaking to a that has been to human insulin in its an at the University of and the lead of a study published in the that are protein By adding a of human to the of 10 they a in that could make insulin in To their not only did the a type of insulin called but also it into active in large 1 of insulin for of The team to their work, to improve the even They are using a to a of The authors believe that this method could other of making like using or But to make it work on a large they will need to and the which will require from health these they a future where a small of these special could insulin for an with a they could the needs of the in just a year. the of the for insulin This was with the of

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.